Gary Patti, the Michael and Tana Powell Associate Professor of Chemistry in Arts & Sciences at Washington University in St. Louis, has been awarded $4.8 million in two separate National Institutes of Health (NIH) grants focused on improving the accessibility of metabolomics — the study of the biochemical reactions that underlie metabolism.

Scientists at Washington University estimate that the number of metabolites present in a data set could be 90 percent smaller than previously estimated.

The National Institutes of Health (NIH) has awarded an eight-year, $5.85 million grant to Gary Patti, associate professor of chemistry in Arts & Sciences at Washington University in St. Louis, for research.

A simple experiment, originally undertaken to test a new methodology, unexpectedly disproved the prevailing notion of cancer metabolism.

The Alfred P. Sloan Foundation announced Feb. 17 that Washington University in St. Louis’ Gary Patti has been awarded a 2014 Sloan Research Fellowship. He is among 126 outstanding U.S. and Canadian researchers selected as fellowship recipients this year. Awarded annually since 1955, the fellowships are given to early-career scientists and scholars whose achievements and potential identify them as rising stars, the next generation of scientific leaders.

Investigators at Washington University and The Scripps Research Institute have announced the launch of a “Global Metabolomic Initiative” to facilitate meta-analyses on studies of the metabolism of bacteria, yeast, plants, animals and people. Although metabolomics has existed as a discipline for only a decade, it has already provided insights into many difficult-to-treat diseases, including chronic pain. Many more are expected to fall out of the meta-analyses.

An experimental anti-cancer regimen combined a diuretic, a Parkinson’s disease medication and a drug ordinarily used to reverse the effect of sedatives. In research conducted at the School of Medicine, the unusual mixture inhibited the growth of aggressive prostate tumors in laboratory mice.

An experimental anti-cancer regimen combined a diuretic, a Parkinson’s disease medication and a drug ordinarily used to reverse the effect of sedatives. In research conducted at Washington University School of Medicine in St. Louis, the unusual mixture inhibited the growth of aggressive prostate tumors in laboratory mice.